Skip to main content

Su Jong Yu

Seoul National University · 医学

研究室紹介

Professor Su Jong Yu's research lab specializes in hepatology and liver cancer, with a strong focus on hepatocellular carcinoma (HCC) and its complex interplay with underlying liver diseases such as hepatitis B virus (HBV) infection and nonalcoholic fatty liver disease (NAFLD). The lab investigates prognostic factors, treatment outcomes, and molecular mechanisms underlying liver carcinogenesis, including the role of viral load, visceral adiposity, and lipid metabolism. It also explores clinical risks associated with targeted therapies, such as rituximab-induced HBV reactivation in lymphoma patients. The research integrates clinical epidemiology, radiological imaging, and molecular profiling to improve risk stratification and personalized management of liver disease.

hepatocellular carcinomaHBV-related HCCnonalcoholic fatty liver diseaseliver fibrosisrituximab-related HBV reactivation

Research Overview

Papers
415
Total Citations
8,874
Papers (5y)
144
Primary Field
医学

Research Output Trend

Figures are computed from collected data and may differ slightly.

Publications per year (5y)
144total
2021
2022
2023
2024
2025
Citations per year (5y)
1,424total
20212022202320242025

Selected Papers

15
1
Review|272 citations·2016
A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016
Su Jong Yu
SJR Q1Clinical and Molecular HepatologyOA

Many guidelines for hepatocellular carcinoma (HCC) have been published and updated globally. In contrast to other cancers, there is a range of treatment options for HCC involving several multidisciplinary care of the patient. Consequently, enormous heterogeneity in management trends has been observed. To support standard care for HCC, we systematically appraised 8 current guidelines for HCC around the world, including 3 guidelines from Asia, 2 from Europe, and 3 from the United States according

HepatologyMedicine
2
Article|157 citations·2018
Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma
Su Jong Yu, Chi Ma, Bernd Heinrich, Zachary J. Brown, Milan Sandhu, Qianfei Zhang, Qiong Fu, David Agdashian, Umberto Rosato, Firouzeh Korangy, Tim F. Greten
SJR Q1Journal of Hepatology
ImmunologyImmunology and Microbiology
3
Article|148 citations·2010
Long-term Prognosis of Combined Hepatocellular and Cholangiocarcinoma After Curative Resection Comparison With Hepatocellular Carcinoma and Cholangiocarcinoma
Jeong‐Hoon Lee, Goh Eun Chung, Su Jong Yu, Sang Youn Hwang, Joon Suk Kim, Hwi Young Kim, Jung‐Hwan Yoon, Hyo-Suk Lee, Nam‐Joon Yi, Kyung‐Suk Suh, Kuhn Uk Lee, Ja–June Jang
SJR Q2Journal of Clinical Gastroenterology

The results of this study indicated that cHCC-CC had a significantly poorer prognosis than HCC and CC even after curative resection.

SurgeryMedicine
4
Article|119 citations·2015
Visceral Obesity Predicts Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
Su Jong Yu, Won Kim, Donghee Kim, Jung‐Hwan Yoon, Kyoung Bun Lee, Jung Ho Kim, Eun Ju Cho, Jeong‐Hoon Lee, Hwi Young Kim, Yoon Jun Kim, Chung Yong Kim
SJR Q3MedicineOA

Nonalcoholic fatty liver disease (NAFLD) is associated with visceral obesity. However, the association between visceral adipose tissue (VAT) area and fibrosis in NAFLD patients has not been completely established. This study was aimed to determine the relationship between the computed tomography-measured VAT area and significant fibrosis in NAFLD patients. A total of 324 NAFLD patients and 132 controls were evaluated by liver biopsy. NAFLD was diagnosed based on histological examinations and alc

EpidemiologyMedicine
5
Review|69 citations·2023
Immunotherapy for hepatocellular carcinoma: Recent advances and future targets
Su Jong Yu
SJR Q1Pharmacology & Therapeutics
OncologyMedicine
6
Article|65 citations·2015
High titers of anti‐HBs prevent rituximab‐related viral reactivation in resolved hepatitis B patient with non‐Hodgkin's lymphoma
Yuri Cho, Su Jong Yu, Eun Ju Cho, Jeong‐Hoon Lee, Tae Min Kim, Dae Seog Heo, Yoon Jun Kim, Jung‐Hwan Yoon
SJR Q1Journal of Medical Virology

Rituximab, an anti-CD20 monoclonal antibody, is associated with an increased risk of hepatitis B virus (HBV) reactivation. This study aimed to determine the predictive factors for rituximab-related HBV reactivation in resolved hepatitis B patients, defined as HBsAg-negative, anti-HBc-positive, and undetectable HBV DNA. Among 840 consecutive patients with CD20-positive B-cell lymphoma who received rituximab-based chemotherapy from 2003 through 2014 at Seoul National University Hospital, 732 patie

EpidemiologyMedicine
7
Review|62 citations·2014
Hepatitis B viral load affects prognosis of hepatocellular carcinoma
Su Jong Yu
SJR Q1World Journal of GastroenterologyOA

Hepatocellular carcinoma (HCC) is a complex disease that is dually challenging to treat due to underlying chronic liver disease in addition to the cancer itself. The prognosis of patients with HCC is determined by intrahepatic tumor status and reserved hepatic function. Hepatitis B virus (HBV) is an established major risk factor of HCC development, and HBV viral load is being increasingly recognized as a prognostic factor in the presence of established HCC. High HBV viral load may affect the pro

EpidemiologyMedicine
8
Article|45 citations·2021
Association between Lipid Profiles and the Incidence of Hepatocellular Carcinoma: A Nationwide Population-Based Study
Yuri Cho, Eun Ju Cho, Jeong‐Ju Yoo, Young Woon Chang, Goh Eun Chung, Su‐Min Jeong, Sang Hyun Park, Kyungdo Han, Dong Wook Shin, Su Jong Yu
SJR Q1CancersOA

BACKGROUND AND AIMS: Altered lipid metabolism has been implicated in the development of hepatocellular carcinoma (HCC). This study investigated the relationships between lipid profiles and HCC development. METHODS: Data were obtained from the Korean National Health Insurance Service from 2009 to 2017. Cox regression analysis was used to examine the hazard ratios of HCC in 8,528,790 individuals who had undergone health check-ups in 2009. RESULTS: During a median of 7.3 years follow-up, 26,891 inc

Cancer ResearchBiochemistry, Genetics and Molecular Biology
9
Article|43 citations·2012
Enhancement of hexokinase II inhibitor-induced apoptosis in hepatocellular carcinoma cells via augmenting ER stress and anti-angiogenesis by protein disulfide isomerase inhibition
Su Jong Yu, Jung‐Hwan Yoon, Jong-In Yang, Eun Ju Cho, Min Sun Kwak, Eun Sun Jang, Jeong‐Hoon Lee, Yoon Jun Kim, Hyo Suk Lee, Chung Yong Kim
SJR Q3Journal of Bioenergetics and Biomembranes
Cell BiologyBiochemistry, Genetics and Molecular Biology
10
Article|43 citations·2022
Association of fatty liver index with all-cause and disease-specific mortality: A nationwide cohort study
Goh Eun Chung, Su‐Min Jeong, Eun Ju Cho, Jeong‐Ju Yoo, Yuri Cho, Kyu Na Lee, Dong Wook Shin, Yoon Jun Kim, Jung‐Hwan Yoon, Kyungdo Han, Su Jong Yu
SJR Q1Metabolism
EpidemiologyMedicine
11
Article|40 citations·2011
Inhibition of hypoxia-inducible carbonic anhydrase-IX enhances hexokinase II inhibitor-induced hepatocellular carcinoma cell apoptosis
Su Jong Yu, Jung‐Hwan Yoon, Jeong‐Hoon Lee, Sun Jung Myung, Eun-sun Jang, Min‐Sun Kwak, Eun Ju Cho, Ja–June Jang, Yoon Jun Kim, Hyo-Suk Lee
SJR Q1Acta Pharmacologica SinicaOA
Molecular BiologyBiochemistry, Genetics and Molecular Biology
12
Article|39 citations·2016
Survival Analysis of Single Large (>5 cm) Hepatocellular Carcinoma Patients: BCLC A versus B
Yuri Cho, Dong Hyun Sinn, Su Jong Yu, Geum Youn Gwak, Ji Hoon Kim, Yang Jae Yoo, Dae Won Jun, Tae Yeob Kim, Hyo Young Lee, Eun Ju Cho, Jeong‐Hoon Lee, Yoon Jun Kim
SJR Q1PLoS ONEOA

This large scale long-term follow-up data shows that single large tumor should be considered as intermediate stage in terms of prognosis. However, in terms of treatment, resection might be the first line treatment option.

HepatologyMedicine
13
Review|38 citations·2015
Effective treatment strategies other than sorafenib for the patients with advanced hepatocellular carcinoma invading portal vein
Su Jong Yu
SJR Q2World Journal of HepatologyOA

Patients with hepatocellular carcinoma (HCC) accompanying portal vein tumor thrombosis (PVTT) have relatively few therapeutic options and an extremely poor prognosis. These patients are classified into barcelona clinic liver cancer stage C and sorafenib is suggested as the standard therapy of care. However, overall survival (OS) gain from sorafenib is unsatisfactory and better treatment modalities are urgently required. Therefore, we critically appraised recent data for the various treatment str

HepatologyMedicine
14
Article|38 citations·2023
Gamma-glutamyl transferase and risk of all-cause and disease-specific mortality: a nationwide cohort study
Eun Ju Cho, Su‐Min Jeong, Goh Eun Chung, Jeong‐Ju Yoo, Yuri Cho, Kyu‐na Lee, Dong Wook Shin, Yoon Jun Kim, Jung‐Hwan Yoon, Kyungdo Han, Su Jong Yu
SJR Q1Scientific ReportsOA

Population-based data regarding the prognostic implication of gamma-glutamyl transferase (GGT) have been inconsistent. We examined the association of GGT with all-cause and disease-specific mortality. Using the Korean nationwide database, we included 9,687,066 subjects without viral hepatitis or cirrhosis who underwent a health examination in 2009. Subjects were classified into three groups by sex-specific tertile of serum GGT levels. The underlying causes of death were classified by 10th Revisi

EpidemiologyMedicine
15
Article|35 citations·2020
Liver enzyme variability and risk of heart disease and mortality: A nationwide population‐based study
Eun Ju Cho, Kyungdo Han, Seung‐Pyo Lee, Dong Wook Shin, Su Jong Yu
SJR Q1Liver International

BACKGROUND & AIMS: Liver enzymes, such as alanine aminotransferase (ALT), aspartate aminotransferase (AST) and γ-glutamyltransferase (GGT), have been suggested as surrogate markers of various cardiovascular diseases. However, previous studies assessed liver enzymes only once at baseline. We investigated the association between liver enzyme variability and the risk of mortality and cardiovascular outcomes in general population. METHODS: A total of 6 496 271 subjects participating in ≥3 health exa

EpidemiologyMedicine

Research Areas

HepatologyEpidemiologyMolecular BiologyCancer ResearchOncologyImmunology

Su Jong Yuの研究をNubintでさらに深く

この研究室の論文をアプリで開き、AIと共に読み、要約し、引用しましょう。